Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) EPS (Weighted Average and Diluted) (2018 - 2025)

Marimed (MRMD) has disclosed EPS (Weighted Average and Diluted) for 8 consecutive years, with -$0.01 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 50.0% to -$0.01 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.03 through Dec 2025, down 50.0% year-over-year, with the annual reading at -$0.04 for FY2025, 33.33% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.01 at Marimed, roughly flat from -$0.01 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.02 in Q2 2021, with the low at -$0.02 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.0, with a median of -$0.0 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) soared 521.76% in 2021, then plummeted 282.27% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.02 in 2021, then soared by 200.0% to $0.02 in 2022, then plummeted by 200.0% to -$0.02 in 2023, then grew by 0.0% to -$0.02 in 2024, then surged by 50.0% to -$0.01 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.01, -$0.01, and -$0.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.